Patents by Inventor Susan L. Kalled
Susan L. Kalled has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11879008Abstract: Provided herein are fusion protein constructs that can bind a complement-associated antigen, comprising a targeting moiety and a complement modulator protein, or a fragment thereof or a variant thereof. The targeting moiety is an antibody or an antigen binding fragment thereof, in some examples. Further provided are methods of using the fusion protein constructs, for example, in treating complement mediation conditions.Type: GrantFiled: June 4, 2021Date of Patent: January 23, 2024Assignee: Q32 Bio Inc.Inventors: Michael Steven Curtis, Michael Storek, Shelia Marie Violette, Susan L. Kalled, Kelly C. Fahnoe, Cheng Ran Huang, Ellen Garber Stark, Frederick Robbins Taylor, Justin Andrew Caravella, Vernon Michael Holers
-
Publication number: 20220213208Abstract: This invention provides antibodies that recognize the B Cell Maturation Antigen (BCMA) and that bind naïve B cells, plasma cells, and/or memory B cells. The invention further provides methods for depleting naïve B cells, plasma cells, and memory B cells, and for treating B cell-related disorders, including lymphomas and autoimmune diseases.Type: ApplicationFiled: July 30, 2021Publication date: July 7, 2022Applicant: Biogen MA Inc.Inventors: Susan L. Kalled, Yen-Ming Hsu
-
Publication number: 20210309728Abstract: Provided herein are fusion protein constructs that can bind a complement-associated antigen, comprising a targeting moiety and a complement modulator protein, or a fragment thereof or a variant thereof. The targeting moiety is an antibody or an antigen binding fragment thereof, in some examples. Further provided are methods of using the fusion protein constructs, for example, in treating complement mediation conditions.Type: ApplicationFiled: June 4, 2021Publication date: October 7, 2021Inventors: Michael Steven Curtis, Michael Storek, Shelia Marie Violette, Susan L. Kalled, Kelly C. Fahnoe, Cheng Ran Huang, Ellen Garber Stark, Frederick Robbins Taylor, Justin Andrew Caravella, Vernon Michael Holers
-
Patent number: 11111307Abstract: This invention provides antibodies that recognize the B Cell Maturation Antigen (BCMA) and that bind naïve B cells, plasma cells, and/or memory B cells. The invention further provides methods for depleting naïve B cells, plasma cells, and memory B cells, and for treating B cell-related disorders, including lymphomas and autoimmune diseases.Type: GrantFiled: July 3, 2018Date of Patent: September 7, 2021Assignee: Biogen MA Inc.Inventors: Susan L. Kalled, Yen-Ming Hsu
-
Patent number: 11053305Abstract: Provided herein are fusion protein constructs that can bind a complement-associated antigen, comprising a targeting moiety and a complement modulator protein, or a fragment thereof or a variant thereof. The targeting moiety is an antibody or an antigen binding fragment thereof, in some examples. Further provided are methods of using the fusion protein constructs, for example, in treating complement mediation conditions.Type: GrantFiled: January 24, 2020Date of Patent: July 6, 2021Assignee: Q32 Bio Inc.Inventors: Michael Steven Curtis, Michael Storek, Shelia Marie Violette, Susan L. Kalled, Kelly C. Fahnoe, Cheng Ran Huang, Ellen Garber Stark, Frederick Robbins Taylor, Justin Andrew Caravella, Vernon Michael Holers
-
Patent number: 11053306Abstract: Provided herein are fusion protein constructs that can bind a complement-associated antigen, comprising a targeting moiety and a complement modulator protein, or a fragment thereof or a variant thereof. The targeting moiety is an antibody or an antigen binding fragment thereof, in some examples. Further provided are methods of using the fusion protein constructs, for example, in treating complement mediation conditions.Type: GrantFiled: September 29, 2020Date of Patent: July 6, 2021Assignee: Q32 Bio Inc.Inventors: Michael Steven Curtis, Michael Storek, Shelia Marie Violette, Susan L. Kalled, Kelly C. Fahnoe, Cheng Ran Huang, Ellen Garber Stark, Frederick Robbins Taylor, Justin Andrew Caravella, Vernon Michael Holers
-
Publication number: 20210009669Abstract: Provided herein are fusion protein constructs that can bind a complement-associated antigen, comprising a targeting moiety and a complement modulator protein, or a fragment thereof or a variant thereof. The targeting moiety is an antibody or an antigen binding fragment thereof, in some examples. Further provided are methods of using the fusion protein constructs, for example, in treating complement mediation conditions.Type: ApplicationFiled: September 29, 2020Publication date: January 14, 2021Inventors: Michael Steven Curtis, Michael Storek, Shelia Marie Violette, Susan L. Kalled, Kelly C. Fahnoe, Cheng Ran Huang, Ellen Garber Stark, Frederick Robbins Taylor, Justin Andrew Caravella, Vernon Michael Holers
-
Publication number: 20200181249Abstract: Provided herein are fusion protein constructs that can bind a complement-associated antigen, comprising a targeting moiety and a complement modulator protein, or a fragment thereof or a variant thereof. The targeting moiety is an antibody or an antigen binding fragment thereof, in some examples. Further provided are methods of using the fusion protein constructs, for example, in treating complement mediation conditions.Type: ApplicationFiled: January 24, 2020Publication date: June 11, 2020Inventors: MICHAEL STEVEN CURTIS, MICHAEL STOREK, SHELIA MARIE VIOLETTE, SUSAN L. KALLED, KELLY C. FAHNOE, CHENG RAN HUANG, ELLEN GARBER STARK, FREDERICK ROBBINS TAYLOR, JUSTIN ANDREW CARAVELLA, VERNON MICHAEL HOLERS
-
Publication number: 20190161552Abstract: This invention provides antibodies that recognize the B Cell Maturation Antigen (BCMA) and that bind naïve B cells, plasma cells, and/or memory B cells. The invention further provides methods for depleting naïve B cells, plasma cells, and memory B cells, and for treating B cell-related disorders, including lymphomas and autoimmune diseases.Type: ApplicationFiled: July 3, 2018Publication date: May 30, 2019Applicant: Biogen MA Inc.Inventors: Susan L. Kalled, Yen-Ming Hsu
-
Publication number: 20170029518Abstract: This invention provides antibodies that recognize the B Cell Maturation Antigen (BCMA) and that bind naïve B cells, plasma cells, and/or memory B cells. The invention further provides methods for depleting naïve B cells, plasma cells, and memory B cells, and for treating B cell-related disorders, including lymphomas and autoimmune diseases.Type: ApplicationFiled: March 9, 2016Publication date: February 2, 2017Applicant: Biogen MA Inc.Inventors: Susan L. Kalled, Yen-Ming Hsu
-
Patent number: 9034324Abstract: This invention provides antibodies that recognize the B Cell Maturation Antigen (BCMA) and that bind naïve B cells, plasma cells, and/or memory B cells. The invention further provides methods for depleting naïve B cells, plasma cells, and memory B cells, and for treating B cell-related disorders, including lymphomas and autoimmune diseases.Type: GrantFiled: March 10, 2010Date of Patent: May 19, 2015Assignee: BIOGEN IDEC MA INC.Inventors: Susan L. Kalled, Yen-Ming Hsu
-
Publication number: 20150125460Abstract: This invention provides antibodies that recognize the B Cell Maturation Antigen (BCMA) and that bind naïve B cells, plasma cells, and/or memory B cells. The invention further provides methods for depleting naïve B cells, plasma cells, and memory B cells, and for treating B cell-related disorders, including lymphomas and autoimmune diseases.Type: ApplicationFiled: January 14, 2015Publication date: May 7, 2015Applicant: BIOGEN IDEC MA INC.Inventors: Susan L. Kalled, Yen-Ming Hsu
-
Publication number: 20140213470Abstract: BAFF plays a central role in acquired immunity. The disclosure identifies BAFF responsive genes that are substantially upregulated by administration of BAFF and substantially downregulated by treatment with a BAFF antagonist. Specific genes are NF-?B2, CD23, H2-M? (the beta chain of H2-DM), Fig-1, and OBF-1. The disclosure provides methods and compositions for monitoring the activity of a BAFF antagonist in a mammal; monitoring BAFF activity in a mammal; identifying a mammal to be treated with a BAFF antagonist; and related uses. Such methods include detecting one or more molecules selected from the group consisting of Fig-1 molecule, OBF-1 molecule, and H2-M? molecule in a biological sample of the mammal, and optionally further detecting NF-?B2 molecule and/or CD23 molecule in the biological sample.Type: ApplicationFiled: November 21, 2013Publication date: July 31, 2014Applicants: GENENTECH, INC., BIOGEN IDEC MA INC.Inventors: Yen-Ming Hsu, Leonid Gorelik, Tatiana Novobrantseva, Joanne Quan, Flavius Martin, Susan L. Kalled
-
Patent number: 8617545Abstract: BAFF plays a central role in acquired immunity. The disclosure identifies BAFF-responsive genes that are substantially upregulated by administration of BAFF and substantially downregulated by treatment with a BAFF antagonist. Specific genes are: NF-?B2, CD23, H2-M? (the beta chain of H2-DM), Fig-1, and OBF-1. The disclosure provides methods and compositions for: monitoring the activity of a BAFF antagonist in a mammal; monitoring BAFF activity in a mammal; identifying a mammal to be treated with a BAFF antagonist; and related uses. Such methods include detecting one or more molecules selected from the group consisting of Fig-1 molecule, OBF-1 molecule, and H2-M? molecule in a biological sample of the mammal, and optionally further detecting NF-?B2 molecule and/or CD23 molecule in the biological sample.Type: GrantFiled: October 12, 2006Date of Patent: December 31, 2013Assignees: Biogen Idec MA Inc., Genentech, Inc.Inventors: Yen-Ming Hsu, Leonid Gorelik, Tatiana Novobrantseva, Joanne Quan, Flavius Martin, Susan L. Kalled
-
Patent number: 8415111Abstract: The present disclosure provides compositions and methods relating to the evaluation of BAFF in a biological sample from a subject.Type: GrantFiled: May 22, 2012Date of Patent: April 9, 2013Assignee: Biogen Idec MA Inc.Inventors: Yen-Ming Hsu, Susan L. Kalled
-
Publication number: 20120231481Abstract: The present disclosure provides compositions and methods relating to the evaluation of BAFF in a biological sample from a subject.Type: ApplicationFiled: May 22, 2012Publication date: September 13, 2012Inventors: Yen-Ming Hsu, Susan L. Kalled
-
Patent number: 8202698Abstract: The present disclosure provides compositions and methods relating to the evaluation of BAFF in a biological sample from a subject.Type: GrantFiled: November 7, 2006Date of Patent: June 19, 2012Assignee: Biogen Idec MA Inc.Inventors: Yen-Ming Hsu, Susan L. Kalled
-
Publication number: 20120082661Abstract: This invention provides antibodies that recognize the B Cell Maturation Antigen (BCMA) and that bind naïve B cells, plasma cells, and/or memory B cells. The invention further provides methods for depleting naïve B cells, plasma cells, and memory B cells, and for treating B cell-related disorders, including lymphomas and autoimmune diseases.Type: ApplicationFiled: March 10, 2010Publication date: April 5, 2012Inventors: Susan L. Kalled, Yen-Ming Hsu
-
Publication number: 20110177093Abstract: The disclosure relates to B-cell maturation antigen (BCMA), a receptor for APRIL and BAFF, and its use as an immunoregulatory agent in treatment of immunological disorders such as multiple sclerosis. The disclosure provides methods and compositions for treating neurodegenerative immunological disorders in mammals by administering soluble BCMA, an antibody against BCMA, or an antibody against a BCMA ligand, e.g., APRIL or BAFF.Type: ApplicationFiled: August 24, 2010Publication date: July 21, 2011Inventors: Susan L. Kalled, Hugh Reid
-
Publication number: 20100330066Abstract: BAFF plays a central role in acquired immunity. The disclosure identifies BAFF-responsive genes that are substantially upregulated by administration of BAFF and substantially downregulated by treatment with a BAFF antagonist. Specific genes are: NF-?B2, CD23, H2-M? (the beta chain of H2-DM), Fig-1, and OBF-1. The disclosure provides methods and compositions for: monitoring the activity of a BAFF antagonist in a mammal; monitoring BAFF activity in a mammal; identifying a mammal to be treated with a BAFF antagonist; and related uses. Such methods include detecting one or more molecules selected from the group consisting of Fig-1 molecule, OBF-1 molecule, and H2-M? molecule in a biological sample of the mammal, and optionally further detecting NF-?B2 molecule and/or CD23 molecule in the biological sample.Type: ApplicationFiled: October 12, 2006Publication date: December 30, 2010Inventors: Yen-Ming Hsu, Leonid Gorelik, Tatiana Novobrantseva, Joanne Quan, Flavius Martin, Susan L. Kalled